MX2017009695A - Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd). - Google Patents

Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd).

Info

Publication number
MX2017009695A
MX2017009695A MX2017009695A MX2017009695A MX2017009695A MX 2017009695 A MX2017009695 A MX 2017009695A MX 2017009695 A MX2017009695 A MX 2017009695A MX 2017009695 A MX2017009695 A MX 2017009695A MX 2017009695 A MX2017009695 A MX 2017009695A
Authority
MX
Mexico
Prior art keywords
individual
osm
methods
osmr
inflammatory bowel
Prior art date
Application number
MX2017009695A
Other languages
English (en)
Spanish (es)
Inventor
Richard WEST Nathaniel
Michael Joseph Owens Benjamin
Nabil Hegazy Ahmed
Margaret Powrie Fiona
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009695(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1501480.6A external-priority patent/GB201501480D0/en
Priority claimed from GB201501511A external-priority patent/GB201501511D0/en
Priority claimed from GBGB1521446.3A external-priority patent/GB201521446D0/en
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2017009695A publication Critical patent/MX2017009695A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/204IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/5412IL-6
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2017009695A 2015-01-29 2016-01-28 Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd). MX2017009695A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1501480.6A GB201501480D0 (en) 2015-01-29 2015-01-29 Biomarker
GB201501511A GB201501511D0 (en) 2015-01-29 2015-01-29 Biomarker
GBGB1521446.3A GB201521446D0 (en) 2015-12-04 2015-12-04 Biomarker
PCT/GB2016/050185 WO2016120625A1 (en) 2015-01-29 2016-01-28 Biomarker

Publications (1)

Publication Number Publication Date
MX2017009695A true MX2017009695A (es) 2018-04-10

Family

ID=55299667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009695A MX2017009695A (es) 2015-01-29 2016-01-28 Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd).

Country Status (8)

Country Link
US (1) US10822406B2 (enExample)
EP (2) EP3250599B1 (enExample)
JP (1) JP6999417B2 (enExample)
KR (1) KR20170132143A (enExample)
CN (1) CN107530431B (enExample)
AU (1) AU2016210996B2 (enExample)
MX (1) MX2017009695A (enExample)
WO (1) WO2016120625A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
JP2021522241A (ja) * 2018-04-25 2021-08-30 キニクサ ファーマシューティカルズ, リミテッド 抗osmrβ抗体の送達による皮膚疾患又は障害の治療
US11779643B2 (en) * 2019-08-28 2023-10-10 Children's Hospital Medical Center Methods and compositions for the treatment of an inflammatory bowel disease
JP7620324B2 (ja) * 2019-08-29 2025-01-23 国立大学法人東北大学 炎症性腸疾患の診断方法、診断プローブ及び診断キット
CN113699187B (zh) * 2020-05-20 2023-08-08 中国科学院微生物研究所 一种肠易激综合征小鼠模型及其应用
KR20230092978A (ko) 2020-10-19 2023-06-26 조에티스 서비시즈 엘엘씨 개 및 고양이 온코스타틴 m 수용체 베타에 대한 항체 및 이의 용도
IL285031A (en) * 2021-07-21 2023-02-01 Yeda Res & Dev Diagnosis of inflammatory bowel diseases
CN116377048B (zh) * 2022-04-22 2024-05-07 广州市妇女儿童医疗中心 S100a8/a9复合体在诊治先天性巨结肠中的应用
WO2025049876A1 (en) * 2023-09-01 2025-03-06 Genentech, Inc. Methods for treating inflammatory bowel disease
WO2025153079A1 (en) * 2024-01-19 2025-07-24 Biomap (Suzhou) Intelligent Technology Limited Method of treatment
CN119955922A (zh) * 2025-01-15 2025-05-09 浙江大学 生物标志物在制备炎症性肠病筛查或亚型检测产品的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693130B2 (en) 1999-02-18 2004-02-17 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6531506B1 (en) 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US5958442A (en) 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US7572896B2 (en) 2005-02-03 2009-08-11 Raven Biotechnologies, Inc. Antibodies to oncostatin M receptor
WO2007143231A2 (en) * 2006-01-10 2007-12-13 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
EP1904050B1 (en) 2005-06-06 2012-11-14 The Regents of The University of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
US20080293582A1 (en) 2006-08-30 2008-11-27 Xilin Li Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel
WO2008028044A2 (en) 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel
WO2010044952A2 (en) 2008-08-25 2010-04-22 Centocor Ortho Biotech Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
CN103209731A (zh) 2010-09-30 2013-07-17 赢创有限公司 药物输送刀片及用于将药物储仓输送到目标部位的方法
PH12013500703A1 (en) 2010-10-13 2013-05-20 Janssen Biotech Inc Human oncostatin m antibodies and methods of use
PL2643352T3 (pl) * 2010-11-23 2018-10-31 Glaxo Group Limited Białka wiążące antygen wiążące onkostatynę M (OSM)
WO2013168829A1 (en) 2012-05-11 2013-11-14 Wakayama Medical University Anti oncostatin m receptor beta antibody
BR112015028338A2 (pt) 2013-05-17 2017-07-25 Genentech Inc métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal
TR201815608T4 (tr) 2013-05-30 2018-11-21 Kiniksa Pharmaceuticals Ltd Onkastatin m reseptörü antijeni bağlayıcı proteinler.

Also Published As

Publication number Publication date
CN107530431B (zh) 2022-01-07
JP2018506528A (ja) 2018-03-08
EP3250599B1 (en) 2021-04-14
US20180022800A1 (en) 2018-01-25
AU2016210996A1 (en) 2017-08-17
WO2016120625A1 (en) 2016-08-04
US10822406B2 (en) 2020-11-03
CN107530431A (zh) 2018-01-02
KR20170132143A (ko) 2017-12-01
JP6999417B2 (ja) 2022-02-04
AU2016210996B2 (en) 2021-08-12
EP3974450A2 (en) 2022-03-30
EP3250599A1 (en) 2017-12-06
EP3974450A3 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
MX2017009695A (es) Objetivo terapeutico y biomarcador en enfermedad inflamatoria intestinal (ibd).
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
EP3542332A4 (en) BLOCK CHAIN SYSTEM FOR SUPPORTING PUBLIC AND PRIVATE TRANSACTIONS IN ACCOUNT MODELS
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
MX392671B (es) Antagonistas de unión a pd-l1 y usos de los mismos para el tratamiento de cáncer
PH12016500331A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
FR3010624B1 (fr) Procede et systeme de cartographie, procede et systeme d'evaluation de l'efficacite d'une stimulation medullaire
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
MX2015009392A (es) Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.
EP3875605C0 (en) METHOD FOR DIAGNOSIS AND PROGNOSIS OF CHRONIC HEART FAILURE
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
MX2024001909A (es) Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX2016008516A (es) Metodos terapeuticos y composiciones.
MX2018010536A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
WO2016030334A3 (en) Methods, agents and compositions for treatment of inflammatory conditions
MX2020006660A (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato.
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
MX384423B (es) Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2).
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
MX2018000528A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
WO2015169973A3 (de) Markersequenzen zur diagnose und stratifizierung von systemische sklerose patienten
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака